Immunotherapy, which uses the patient’s immune system to fight tumors, shows superior clinical results than conventional treatment. However, since tumors have various means of immune evasion, the proportion of patients responding to immunotherapy remains low or moderate. Therefore, through the convergence of cancer immunotherapy and biomaterials, this research group explores ways to control the immune system spatiotemporally and maximize the therapeutic effect.